Principal Investigator(s):Harriet L Robinson
Objective:To evaluate the safety of the vaccines during the three phases of the study. A secondary objective is to evaluate the immunogenicity of the vaccines during the vaccination phase of the study.
Prevention Option(s):Therapeutic Vaccines
Study Design:Open label
Arms and Assigned Interventions
DescriptionTwo doses IM (intramuscular) of 3 mg JS7 DNA at weeks 1 and 9, followed by two doses IM of 10(8) MVA62B vaccine at weeks 17 and 25. JS7 plasmid DNA and MVA62B vaccine.
Mode of DeliveryIntramuscular
Official Code: NCT01378156
Trial Sponsors: AIDS Research Alliance, AIDS Research Consortium of Atlanta, GeoVax Labs, University of Alabama at Birmingham
Start Date
End Date
June 30, 2010
May 31, 2014
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women, People Living with HIV